Overview
Elin Borgen practices practicing medicine in Nydalen, Norway.
Ms. Borgen is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Breast Cancer, Febrile Neutropenia, and Pancreatic Cancer.
She is actively involved in clinical research, co-authoring 54 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Elin F. Borgen
Is Elin F. Borgen a top-rated expert for Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Elin F. Borgen is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Elin F. Borgen participate in research or clinical trials?
Yes. Elin F. Borgen has published 54 articles and abstracts on conditions like Breast Cancer. You can view a list of Elin F. Borgen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Breast CancerMs. Borgen isAdvanced. Learn about Breast Cancer.
- Experienced
- Febrile NeutropeniaMs. Borgen isExperienced. Learn about Febrile Neutropenia.
- Pancreatic CancerMs. Borgen isExperienced. Learn about Pancreatic Cancer.